Roscrea biopharma firm secures $100m investment ahead of plans for IPO
The Tipperary-based company aims to list on the US stock market within the coming months and believes its new drug candidates are worth at least $1 billion
Renexxion, a Roscrea-headquartered biopharma company, has secured $100 million (€92.5 million) in funding as part of a move that will see it list on the US stock market within the coming months.
The company, which is the brainchild of Tipperary native Peter Milner, aims to bring a new gastrointestinal drug to market that it believes will achieve sales of at least $1 billion.
A former EY Entrepreneur of the Year finalist, Milner sold his first ...